SynAct Pharma AB

As of June 30, 2026, SynAct Pharma AB carries a market capitalization of 1.18B, placing it among publicly traded companies globally. Its enterprise value stands at 1.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SynAct Pharma AB's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, SynAct Pharma AB has 56.00M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, SynAct Pharma AB maintains a current ratio of 4.10, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, SynAct Pharma AB recorded an income tax benefit of -7.91M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, SynAct Pharma AB's stock has declined approximately 15.94% over the past 52 weeks. The 50-day moving average sits at 18.32, while the 200-day moving average is 18.09.

As of June 30, 2026, SynAct Pharma AB holds 14.23M in cash and equivalents against 929,000.00 in total debt, resulting in a net debt position of -14.23M. Total book value stands at 171.67M, with working capital of 30.38M providing operational flexibility.

SynAct Pharma AB's most recent stock split took place on December 16, 2024 with a 549:554 split ratio.